Fmr LLC Buys 44,199 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Fmr LLC lifted its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 34.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 173,595 shares of the company’s stock after acquiring an additional 44,199 shares during the quarter. Fmr LLC owned about 0.13% of Organogenesis worth $496,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in ORGO. Pallas Capital Advisors LLC bought a new stake in Organogenesis during the second quarter worth approximately $38,000. Delap Wealth Advisory LLC acquired a new stake in shares of Organogenesis in the second quarter worth $40,000. Intech Investment Management LLC bought a new stake in shares of Organogenesis during the 3rd quarter worth $43,000. Allspring Global Investments Holdings LLC grew its stake in Organogenesis by 4,989.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after buying an additional 15,369 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Organogenesis by 46.1% in the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after acquiring an additional 7,678 shares during the period. Institutional investors and hedge funds own 49.57% of the company’s stock.

Insider Buying and Selling

In related news, CEO Gary S. Gillheeney sold 55,615 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $3.36, for a total transaction of $186,866.40. Following the transaction, the chief executive officer now directly owns 3,044,779 shares in the company, valued at $10,230,457.44. The trade was a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 278,116 shares of company stock valued at $991,190. 36.90% of the stock is owned by company insiders.

Organogenesis Stock Down 9.2 %

ORGO stock opened at $3.24 on Thursday. The stock has a market capitalization of $429.55 million, a price-to-earnings ratio of -54.00 and a beta of 1.73. The company has a 50-day moving average of $3.45 and a two-hundred day moving average of $3.01. Organogenesis Holdings Inc. has a 52-week low of $2.16 and a 52-week high of $4.70. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.11. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the prior year, the company earned $0.02 EPS. As a group, equities research analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.